ATE339438T1 - Substanziell kristalline form von melagatran - Google Patents

Substanziell kristalline form von melagatran

Info

Publication number
ATE339438T1
ATE339438T1 AT00946687T AT00946687T ATE339438T1 AT E339438 T1 ATE339438 T1 AT E339438T1 AT 00946687 T AT00946687 T AT 00946687T AT 00946687 T AT00946687 T AT 00946687T AT E339438 T1 ATE339438 T1 AT E339438T1
Authority
AT
Austria
Prior art keywords
melagatran
crystalline form
substantial crystalline
substantial
crystalline
Prior art date
Application number
AT00946687T
Other languages
English (en)
Inventor
Lena Hedstroem
Anita Lundblad
Sofia Nagard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE339438T1 publication Critical patent/ATE339438T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00946687T 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran ATE339438T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms

Publications (1)

Publication Number Publication Date
ATE339438T1 true ATE339438T1 (de) 2006-10-15

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946687T ATE339438T1 (de) 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran

Country Status (33)

Country Link
US (1) US6479078B1 (de)
EP (1) EP1196431B1 (de)
JP (1) JP2003503508A (de)
KR (1) KR20020020765A (de)
CN (1) CN100537598C (de)
AR (1) AR035553A1 (de)
AT (1) ATE339438T1 (de)
AU (1) AU765614B2 (de)
BR (1) BR0012035A (de)
CA (1) CA2376944A1 (de)
CY (1) CY1107542T1 (de)
CZ (1) CZ20014722A3 (de)
DE (1) DE60030723T2 (de)
DK (1) DK1196431T3 (de)
EE (1) EE200100646A (de)
ES (1) ES2270849T3 (de)
HK (1) HK1045529B (de)
HU (1) HUP0202322A3 (de)
IL (1) IL146972A0 (de)
IS (1) IS6215A (de)
MX (1) MXPA01013441A (de)
MY (1) MY122760A (de)
NO (1) NO20016419L (de)
NZ (1) NZ516187A (de)
PL (1) PL352872A1 (de)
PT (1) PT1196431E (de)
RU (1) RU2243973C2 (de)
SE (1) SE9902550D0 (de)
SK (1) SK18832001A3 (de)
TR (1) TR200103855T2 (de)
TW (1) TWI250991B (de)
WO (1) WO2001002426A1 (de)
ZA (1) ZA200109944B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005051925A1 (ja) * 2003-11-27 2005-06-09 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶及びその製造方法
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
ES2270849T3 (es) 2007-04-16
AU6040800A (en) 2001-01-22
HUP0202322A2 (en) 2002-10-28
WO2001002426A1 (en) 2001-01-11
SE9902550D0 (sv) 1999-07-02
MY122760A (en) 2006-05-31
HK1045529B (en) 2007-02-23
PL352872A1 (en) 2003-09-08
US6479078B1 (en) 2002-11-12
DE60030723T2 (de) 2007-11-08
PT1196431E (pt) 2007-01-31
CN100537598C (zh) 2009-09-09
EP1196431B1 (de) 2006-09-13
TWI250991B (en) 2006-03-11
ZA200109944B (en) 2003-03-03
NZ516187A (en) 2004-09-24
AR035553A1 (es) 2004-06-16
JP2003503508A (ja) 2003-01-28
DK1196431T3 (da) 2006-12-11
CA2376944A1 (en) 2001-01-11
HK1045529A1 (en) 2002-11-29
TR200103855T2 (tr) 2002-04-22
EE200100646A (et) 2003-02-17
CY1107542T1 (el) 2013-03-13
SK18832001A3 (sk) 2002-10-08
RU2243973C2 (ru) 2005-01-10
NO20016419D0 (no) 2001-12-28
CZ20014722A3 (cs) 2002-05-15
MXPA01013441A (es) 2002-07-02
IS6215A (is) 2001-12-27
DE60030723D1 (de) 2006-10-26
CN1359389A (zh) 2002-07-17
BR0012035A (pt) 2002-03-19
NO20016419L (no) 2002-03-01
AU765614B2 (en) 2003-09-25
HUP0202322A3 (en) 2003-04-28
EP1196431A1 (de) 2002-04-17
IL146972A0 (en) 2002-08-14
KR20020020765A (ko) 2002-03-15

Similar Documents

Publication Publication Date Title
DK1261585T3 (da) Substituerede indol-Mannichbaser
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
EE200200224A (et) Uudsed ühendid
LV12752A (lv) Heterocyclic aromatic compounds useful as growth hormone secretagogues
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
DK1202953T3 (da) Substituerede 2-dialkylaminoalkylbiphenylderivater
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
ATE261431T1 (de) Kristalline form von (s)-2-ethoxy-3-4-(2-4- methansulfonyloxyphenyl-ethoxy)phenyl)propansäu e
DE60038118D1 (de) Formulierungen von wachstumshormonen
ATE339438T1 (de) Substanziell kristalline form von melagatran
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60026931D1 (de) Ausrichtung von Ausdrucken
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
EE200100381A (et) Morfolinobensamiidi uued soolad
PT1175417E (pt) Compostos substituidos de benzolactamas
DE69940563D1 (de) Wachstum von aluminium-einkristallen
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
SE9904417D0 (sv) Crystalline form
DE60038936D1 (de) Einkristallziehvorrichtung
EE200200053A (et) Isoretinoiini valmistamise protsess
DK1191025T3 (da) Krystaller af lansoprazol
SE9902194D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196431

Country of ref document: EP

REN Ceased due to non-payment of the annual fee